http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003228642-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-35 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2002-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76be02f3cfb94ca2873e855e7b5205c6 |
| publicationDate | 2003-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003228642-A1 |
| titleOfInvention | Crohn's disease treatment and efficacy prediction methods |
| abstract | A method for determining a potential efficacy of an administration of immunotherapy for treating Crohn's disease includes screening for a presence of Mycobacterium avium ss. paratuberculosis (MAP) in a serum of a patient. In another embodiment, Crohn's disease is treated by screening for a presence of MAP in a serum of a patient and avoiding a use of immunotherapy as a primary treatment if the patient screens serologically positive for MAP. Preferably, the patient is treated with a regimen of antibiotics to eradicate a presence of MAP. Then, if necessary, immunotherapy may be undertaken, preferably following a regimen of probiotics. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009111116-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7902350-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110170050-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016016002-A1 |
| priorityDate | 2002-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.